UNSPSC 51314102: Temelastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H24BrN5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BF6IGI53XH, chemically known as 4(1h)-pyrimidinone, 2-((4-(5-bromo-3-methyl-2-pyridinyl)butyl)amino)-5-((6-methyl-3-pyridinyl)methyl)- but generally known as temelastine, which bears US NIH Compound Identifier 55482. European Medicines Agency schedules Temelastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10882MIG.

UNSPSC 51314102 Temelastine is a Commodity code under which state and local governments procure naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter health products for community health, emergency response, and employee benefit programs. The code sees activity across health departments, county public health agencies, and multistate cooperative purchasing alliances acquiring pharmaceutical products, naloxone kits, and drug disposal systems to support public health initiatives and pharmacy benefit programs.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023 and a two-year initial contract term with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on implementing a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, soliciting vendor capabilities around direct contracting outside existing pharmacy benefit manager relationships and outcomes-based pricing models; this exploratory RFI informed future formal procurement strategy rather than representing an immediate award. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with proposals due March 26, 2026; the contract requires vendors to work through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), certify cGMP and Drug Supply Chain Security Act compliance, maintain $5 million commercial general liability insurance, and accept a 3 percent administrative fee on all purchases, with awards effective July 1, 2026.